Recent Posts
- Principles of biological computation: from circadian clock to evolution
- The science and engineering of biological computation: from process to software to DNA-based neural networks
- Elements of biological computation & stochastic thermodynamics of life
- Rationality, the Bayesian mind and their limits
- Web of C-lief: conjectures vs. model assumptions vs. scientific beliefs
- Idealization vs abstraction for mathematical models of evolution
- Allegory of the replication crisis in algorithmic trading
- 668,215 views
Join 2,752 other subscribers
Contributing authors
-
Abel Molina
-
Alexandru Strimbu
-
Alexander Yartsev
-
Eric Bolo
-
David Robert Grimes
-
Forrest Barnum
-
Jill Gallaher
-
Julian Xue
-
Artem Kaznatcheev
-
Keven Poulin
-
Marcel Montrey
-
Matthew Wicker
-
Dan Nichol
-
Philip Gerlee
-
Piotr MigdaĆ
-
Robert Vander Velde
-
Rob Noble
-
Sergio Graziosi
-
Max Hartshorn
-
Thomas Shultz
-
Vincent Cannataro
-
Yunjun Yang
Causes and costs in biological vs clinical resistance
December 14, 2018 by Artem Kaznatcheev 3 Comments
This Wednesday, on These few lines, Rob Noble warned of the two different ways in which the term de novo resistance is used by biologists and clinicians. The biologist sees de novo resistance as new genetic resistance arising after treatment has started. The clinician sees de novo resistance as a tumour that is not responsive to treatment from the start. To make matters even more confusing, Hitesh Mistry points to a further interpretation among pharmocologists: they refer to the tumour remaining after a partial but incomplete response to treatment as de novo resistant. Clearly this is a mess!
But I think this is an informative mess. I don’t think it is a matter of people accidentally overloading the same word. Instead, I think it reflects a conceptual difference in how biologists and clinicians think about resistance. A difference that is a bit akin to the difference between reductive and effective theories. It is also a difference that I had to deal with during the revisions of our recent work on measuring the games played by treatment sensitive and treatment resistance non-small cell lung cancer (Kaznatcheev et al., 2018).
Read more of this post
Filed under Commentary, Preliminary Tagged with mathematical oncology, operationalization